Cargando…

Minor HIV-1 Variants with the K103N Resistance Mutation during Intermittent Efavirenz-Containing Antiretroviral Therapy and Virological Failure

The impact of minor drug-resistant variants of the type 1 immunodeficiency virus (HIV-1) on the failure of antiretroviral therapy remains unclear. We have evaluated the importance of detecting minor populations of viruses resistant to non-nucleoside reverse-transcriptase inhibitors (NNRTI) during in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delobel, Pierre, Saliou, Adrien, Nicot, Florence, Dubois, Martine, Trancart, Stéphanie, Tangre, Philippe, Aboulker, Jean-Pierre, Taburet, Anne-Marie, Molina, Jean-Michel, Massip, Patrice, Marchou, Bruno, Izopet, Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124548/ https://www.ncbi.nlm.nih.gov/pubmed/21738752 http://dx.doi.org/10.1371/journal.pone.0021655

Ejemplares similares

Early changes in coagulation but not inflammatory biomarkers under intermittent ART: the randomized ANRS 106 WINDOW trial
por: Gallien, Sébastien, et al.
Publicado: (2014)

HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy
por: Mavigner, Maud, et al.
Publicado: (2009)

Genotypic prediction of HIV-1 subtype D tropism
por: Raymond, Stéphanie, et al.
Publicado: (2011)

Position-specific automated processing of V3 env ultra-deep pyrosequencing data for predicting HIV-1 tropism
por: Jeanne, Nicolas, et al.
Publicado: (2015)

COVID-19, Virology and Geroscience: A Perspective
por: Vellas, Camille, et al.
Publicado: (2020)

Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship
por: Bhatt, Nilesh B., et al.
Publicado: (2015)

A severe monkeypox infection in a patient with an advanced HIV infection treated with tecovirimat: clinical and virological outcome
por: Viguier, Clément, et al.
Publicado: (2022)

The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa
por: Shearer, Kate, et al.
Publicado: (2014)

Performance comparison of next-generation sequencing platforms for determining HIV-1 coreceptor use
por: Raymond, Stéphanie, et al.
Publicado: (2017)

Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children
por: Bienczak, Andrzej, et al.
Publicado: (2016)

Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1
Publicado: (2019)

A case report of isolated lymphadenopathy revealing localized leishmanial lymphadenopathy in an asthenic 25-year-old man
por: Hurlot, Quentin, et al.
Publicado: (2016)

More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort
por: Rokx, Casper, et al.
Publicado: (2014)

Zika Virus Infection and Prolonged Viremia in Whole-Blood Specimens
por: Mansuy, Jean Michel, et al.
Publicado: (2017)

Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers
por: Migueres, Marion, et al.
Publicado: (2020)

Simplified Assessment of Antiretroviral Adherence and Prediction of Virological Efficacy in HIV-Infected Patients in Cambodia
por: Segeral, Olivier, et al.
Publicado: (2010)

Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals
por: Cain, Lauren E., et al.
Publicado: (2016)

Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission
por: Nyakato, Patience, et al.
Publicado: (2020)

Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi‐centre 48‐week efficacy and safety study in Thailand
por: Phongsamart, Wanatpreeya, et al.
Publicado: (2022)

Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study
por: Bonnet, Eric, et al.
Publicado: (2013)

Efavirenz and neuropsychiatric effects
por: Dheda, Mukesh
Publicado: (2017)

Efavirenz, dysrhythmia and HIV
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Virological outcomes in ARV-naïve patients switching or not from a first successful boosted PI-regimen to efavirenz, nevirapine or abacavir regimens
por: Bommenel, T, et al.
Publicado: (2010)

Virological failure of staggered and simultaneous treatment interruption in HIV patients who began Efavirenz-based regimens after allergic reactions to nevirapine
por: Siripassorn, Krittaecho, et al.
Publicado: (2013)

Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV
por: Stirrup, Oliver T, et al.
Publicado: (2019)

1020. Higher efavirenz mid-dose plasma concentration is associated with less weight gain among virologically suppressed people living with HIV
por: Huang, Wei-chieh, et al.
Publicado: (2020)

Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens
por: De La Cruz, Justin, et al.
Publicado: (2019)

Efavirenz: History, Development and Future
por: Costa, Bárbara, et al.
Publicado: (2022)

Influence of age on the spread of SARS-CoV-2 variant B.1.1.7
por: Dimeglio, Chloé, et al.
Publicado: (2021)

French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults
por: Hoen, Bruno, et al.
Publicado: (2014)

Comparative Safety and Changes in Immunologic and Virologic Parameters of Dolutegravir versus Efavirenz-Based Antiretroviral Therapies Among HIV Patients: A Retrospective Cohort Study
por: Ayal, Melese Alemnew, et al.
Publicado: (2023)

Risk of Cardiovascular Events Among Patients Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

Bach, J. S. Suite in c minor for flute and piano /
por: Pierre Rampal, Jean

Rapid and persistent selection of the K103N mutation as a majority quasispecies in a HIV1-patient exposed to efavirenz for three weeks: a case report and review of the literature
por: Polilli, Ennio, et al.
Publicado: (2009)

HIV-1 Tat Protein Induces Production of Proinflammatory Cytokines by Human Dendritic Cells and Monocytes/Macrophages through Engagement of TLR4-MD2-CD14 Complex and Activation of NF-κB Pathway
por: Ben Haij, Nawal, et al.
Publicado: (2015)

Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial
por: de Castro, Nathalie, et al.
Publicado: (2016)

Plasma Concentrations, Efficacy and Safety of Efavirenz in HIV-Infected Adults Treated for Tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA Trial)
por: Borand, Laurence, et al.
Publicado: (2014)

Influence of the Efavirenz Micronization on Tableting and Dissolution
por: Pinto, Eduardo Costa, et al.
Publicado: (2012)

Influence of Milling Process on Efavirenz Solubility
por: Zaini, Erizal, et al.
Publicado: (2017)

Symphony No. 103/
por: Haydn, Joseph

Cannot write session to /tmp/vufind_sessions/sess_4f70o7ndqtmlf79j969v1tpp62